vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and MEDALLION FINANCIAL CORP (MFIN). Click either name above to swap in a different company.
MEDALLION FINANCIAL CORP is the larger business by last-quarter revenue ($70.6M vs $47.7M, roughly 1.5× IRONWOOD PHARMACEUTICALS INC). MEDALLION FINANCIAL CORP runs the higher net margin — 17.3% vs -4.8%, a 22.1% gap on every dollar of revenue. On growth, MEDALLION FINANCIAL CORP posted the faster year-over-year revenue change (25.4% vs -47.3%). Over the past eight quarters, MEDALLION FINANCIAL CORP's revenue compounded faster (15.0% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
Mahindra & Mahindra Financial Services Limited (MMFSL) is an Indian rural non-banking financial company headquartered in Mumbai. It is amongst the top tractor financers in India, with 1000+ offices across the country.
IRWD vs MFIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $70.6M |
| Net Profit | $-2.3M | $12.2M |
| Gross Margin | — | — |
| Operating Margin | 14.3% | 29.3% |
| Net Margin | -4.8% | 17.3% |
| Revenue YoY | -47.3% | 25.4% |
| Net Profit YoY | -200.9% | 20.3% |
| EPS (diluted) | $0.01 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.7M | $70.6M | ||
| Q3 25 | $122.1M | $58.7M | ||
| Q2 25 | $85.2M | $62.6M | ||
| Q1 25 | $41.1M | $63.0M | ||
| Q4 24 | $90.5M | $56.3M | ||
| Q3 24 | $91.6M | $53.3M | ||
| Q2 24 | $94.4M | $51.0M | ||
| Q1 24 | $74.9M | $53.3M |
| Q4 25 | $-2.3M | $12.2M | ||
| Q3 25 | $40.1M | $7.8M | ||
| Q2 25 | $23.6M | $11.1M | ||
| Q1 25 | $-37.4M | $12.0M | ||
| Q4 24 | $2.3M | $10.1M | ||
| Q3 24 | $3.6M | $8.6M | ||
| Q2 24 | $-860.0K | $7.1M | ||
| Q1 24 | $-4.2M | $10.0M |
| Q4 25 | 14.3% | 29.3% | ||
| Q3 25 | 61.8% | 33.2% | ||
| Q2 25 | 53.2% | 31.1% | ||
| Q1 25 | -70.7% | 32.1% | ||
| Q4 24 | 34.8% | 32.8% | ||
| Q3 24 | 28.0% | 26.6% | ||
| Q2 24 | 26.5% | 24.3% | ||
| Q1 24 | 14.7% | 33.6% |
| Q4 25 | -4.8% | 17.3% | ||
| Q3 25 | 32.8% | 13.2% | ||
| Q2 25 | 27.7% | 17.7% | ||
| Q1 25 | -90.9% | 19.1% | ||
| Q4 24 | 2.5% | 18.0% | ||
| Q3 24 | 4.0% | 16.1% | ||
| Q2 24 | -0.9% | 13.9% | ||
| Q1 24 | -5.6% | 18.8% |
| Q4 25 | $0.01 | $0.50 | ||
| Q3 25 | $0.23 | $0.32 | ||
| Q2 25 | $0.14 | $0.46 | ||
| Q1 25 | $-0.23 | $0.50 | ||
| Q4 24 | $0.03 | $0.43 | ||
| Q3 24 | $0.02 | $0.37 | ||
| Q2 24 | $-0.01 | $0.30 | ||
| Q1 24 | $-0.03 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $136.3M |
| Total DebtLower is stronger | — | $216.0M |
| Stockholders' EquityBook value | $-261.8M | $408.6M |
| Total Assets | $396.9M | $3.0B |
| Debt / EquityLower = less leverage | — | 0.53× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $215.5M | $136.3M | ||
| Q3 25 | $140.4M | $72.5M | ||
| Q2 25 | $92.9M | $110.4M | ||
| Q1 25 | $108.5M | $131.5M | ||
| Q4 24 | $88.6M | $98.2M | ||
| Q3 24 | $88.2M | $120.6M | ||
| Q2 24 | $105.5M | $87.7M | ||
| Q1 24 | $121.5M | $54.8M |
| Q4 25 | — | $216.0M | ||
| Q3 25 | $199.5M | $215.7M | ||
| Q2 25 | $199.3M | $199.9M | ||
| Q1 25 | $199.2M | $199.7M | ||
| Q4 24 | $199.0M | $232.2M | ||
| Q3 24 | $198.8M | $232.0M | ||
| Q2 24 | $198.6M | $230.8M | ||
| Q1 24 | $398.3M | $225.6M |
| Q4 25 | $-261.8M | $408.6M | ||
| Q3 25 | $-264.2M | $397.4M | ||
| Q2 25 | $-308.2M | $389.9M | ||
| Q1 25 | $-334.1M | $380.2M | ||
| Q4 24 | $-301.3M | $370.2M | ||
| Q3 24 | $-311.3M | $362.4M | ||
| Q2 24 | $-321.7M | $354.0M | ||
| Q1 24 | $-330.5M | $349.0M |
| Q4 25 | $396.9M | $3.0B | ||
| Q3 25 | $396.1M | $2.9B | ||
| Q2 25 | $342.9M | $2.9B | ||
| Q1 25 | $327.2M | $2.8B | ||
| Q4 24 | $350.9M | $2.9B | ||
| Q3 24 | $389.5M | $2.9B | ||
| Q2 24 | $395.6M | $2.8B | ||
| Q1 24 | $438.8M | $2.6B |
| Q4 25 | — | 0.53× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.53× | ||
| Q4 24 | — | 0.63× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.65× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $126.3M |
| Free Cash FlowOCF − Capex | $74.6M | — |
| FCF MarginFCF / Revenue | 156.3% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 10.35× |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $74.6M | $126.3M | ||
| Q3 25 | $47.6M | $67.0M | ||
| Q2 25 | $-15.1M | $-10.7M | ||
| Q1 25 | $20.0M | $36.3M | ||
| Q4 24 | $15.2M | $108.7M | ||
| Q3 24 | $9.9M | $24.6M | ||
| Q2 24 | $33.5M | $27.6M | ||
| Q1 24 | $45.0M | $32.3M |
| Q4 25 | $74.6M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $-15.1M | — | ||
| Q1 25 | $19.9M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $9.9M | — | ||
| Q2 24 | $33.4M | — | ||
| Q1 24 | $44.9M | — |
| Q4 25 | 156.3% | — | ||
| Q3 25 | 39.0% | — | ||
| Q2 25 | -17.7% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.8% | — | ||
| Q2 24 | 35.4% | — | ||
| Q1 24 | 60.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 10.35× | ||
| Q3 25 | 1.19× | 8.63× | ||
| Q2 25 | -0.64× | -0.97× | ||
| Q1 25 | — | 3.02× | ||
| Q4 24 | 6.74× | 10.72× | ||
| Q3 24 | 2.71× | 2.86× | ||
| Q2 24 | — | 3.89× | ||
| Q1 24 | — | 3.22× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
